[HTML][HTML] Mechanism of hypoxia-specific cytotoxicity of procaspase-3 fused with a VHL-mediated protein destruction motif of HIF-1α containing Pro564

H Harada, S Kizaka-Kondoh, M Hiraoka - FEBS letters, 2006 - Elsevier
procaspase-3 fused with ODD 548–603 and HIV-Tat protein-transduction domain (PTD). The
final product was named TOP3 (Tat-ODD-Procaspase-3) [… type-1 Tat protein and efficiently …

Tumor hypoxia: a target for selective cancer therapy

S Kizaka‐Kondoh, M Inoue, H Harada… - Cancer …, 2003 - Wiley Online Library
… and hypoxia-specific strategies, are summarized in Table 1. … we chose an endogenous
cytotoxic protein, procaspase-3, which is … HIF-1α targeted for VHL-mediated destruction by proline …

Imaging and targeting of the hypoxia-inducible factor 1-active microenvironment

S Kizaka-Kondoh, S Tanaka… - Journal of toxicologic …, 2009 - jstage.jst.go.jp
Mechanism of hypoxia-specific cytotoxicity of procaspase-3 fused with a VHL-mediated
protein destruction motif of HIF-1α containing Pro564. FEBS Letter. 580: 5718–5722. …

Pathophysiological response to hypoxia—from the molecular mechanisms of malady to drug discovery: hypoxia-inducible factor-1 (HIF-1)-active cells as a target for …

S Kizaka-Kondoh, T Kuchimaru… - Journal of pharmacological …, 2011 - Elsevier
… of the fusion protein into cells and delivery of the fusion protein to … The procaspase-3 domain
is an inactive proenzyme form of … PTD–ODD–procaspase-3 has been shown to specifically …

Significance of HIF-1-active cells in angiogenesis and radioresistance

H Harada, S Kizaka-Kondoh, G Li, S Itasaka, K Shibuya… - Oncogene, 2007 - nature.com
… We have previously reported that procaspase-3 fused with a von … The ODD domain contains
a VHL-mediated protein … The stability of TOP3 is regulated by the same mechanism as HIF-…

The HIF-1-active microenvironment: an environmental target for cancer therapy

S Kizaka-Kondoh, S Tanaka, H Harada… - Advanced drug delivery …, 2009 - Elsevier
… reported that fusion with a VHL-mediated protein destruction … has to enter cells to undergo
the ODD regulatory mechanism… an endogenous cytotoxic protein procaspase-3, which is a …

Hypoxia: a double-edged sword in cancer therapy

H Manoochehri Khoshinani, S Afshar… - Cancer …, 2016 - Taylor & Francis
… , hypoxia-activated prodrugs, hypoxia-specific gene therapy, and hypoxia-targeting fusion
Procaspase-3 can be used as a cytotoxic domain of fusion protein. For overcoming the …

Development of a novel fluorescent imaging probe for tumor hypoxia by use of a fusion protein with oxygen-dependent degradation domain of HIF-1alpha

S Tanaka, S Kizaka-Kondoh… - … and Optical Probes …, 2007 - spiedigitallibrary.org
… To evaluate the efficacy of PTDODD fusion protein as a hypoxia-specific probe, we …
Mechanism of hypoxia-specific cytotoxicity of procaspase-3 fused with a VHL-mediated protein

Selective killing of hypoxia-inducible factor-1–active cells improves survival in a mouse model of invasive and metastatic pancreatic cancer

S Kizaka-Kondoh, S Itasaka, L Zeng, S Tanaka… - Clinical Cancer …, 2009 - AACR
… We developed and validated a fusion protein, TAT-ODD-procaspase-3 (TOP3), to …
Mechanism of hypoxia-specific cytotoxicity of procaspase-3 fused with a VHL-mediated protein

Protein transduction domain-mediated delivery of anticancer proteins

H Harada, M Hiraoka - Pharmaceutical Perspectives of Cancer …, 2009 - Springer
… of the mechanism in the PTD-mediated internalization [57]. … the Tat–ODD fusion protein with
cytotoxicity shows a hypoxia-… with the resultant fusion protein, Tat–ODD–procaspase-3 (TOP3…